LLY Apr 2023 330.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

10.54

-1.12

(-9.61%)

As of 02:13PM EST. Market open.

Loading interactive chart…

Simply Wall St.
Eli Lilly (NYSE:LLY) shareholders have earned a 37% CAGR over the last five years
We think all investors should try to buy and hold high quality multi-year winners. And highest quality companies can...
Zacks
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
Zacks
FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.